

LIST OF REFERENCES CITED BY APPLICANT
(Use separate sheets if necessary)

ATTY DOCKET NO.
11068-035-999

APPLICATION NO
09/591,899

APPLICANT
Parkin *et al.*

FILING DATE
June 12, 2000

GROUP
1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SF	B01	5,436,131	7/95	Condra <i>et al.</i>	435	7.4	
	B02	6,103,462	8/00	Paulous <i>et al.</i>	435	5	
	B03	20020064838	5/02	Parkin <i>et al.</i>	435	9.4	
	B04	20030108857	6/03	Parkin <i>et al.</i>	435	8	
SF	B05	20040106106	6/04	Parkin <i>et al.</i>	435	5	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SF	B06	WO99/67427	6/99	PCT				
	B07	WO00/78996	12/00	PCT				
	B08	WO02/22076	3/02	PCT				
	B09	WO02/068618	9/02	PCT				
	B10	WO02/099387	12/02	PCT				
	B11	WO03/070700	8/03	PCT				
	B12	WO04/003512	1/04	PCT				
	B13	WO04/003514	1/04	PCT				
	B14	Int'l Search Report for PCT/US00/17178	12/00	PCT				
	B15	Int'l Search Report for PCT/US02/18684	1/03	PCT				
	B16	Int'l Search Report for PCT/US03/04362	12/04	PCT				
SF	B17	Int'l Search Report for PCT/US03/21023	7/04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


SF	B18	Carrillo <i>et al.</i> , (1998), "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor," <i>Journal of Virology</i> , 72(9): 7532-41.
	B19	Condra <i>et al.</i> , (1996), "Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor," <i>Journal of Virology</i> , 70(12): 8270-76
	B20	Genbank Accession Number P12497 POL Polyprotein (2004)
	B21	Genbank Accession Number AF324493 HIV-1 vector pNL4...[gi:12831134] (2001).
	B22	Gervais, <i>et al.</i> , (1997), "A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility <i>in Vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 94: 4653-4658.
	B23	Gong <i>et al.</i> , (2000), "In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632," <i>Antimicrobial Agents and Chemotherapy</i> , 44(9): 2319-26.
	B24	Gunthard, <i>et al.</i> , (1998), "Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1 <i>pol</i> From Clinical Samples," <i>Aids Research and Human Retroviruses</i> , 14(10): 869-876.
SF	B25	Haubrich <i>et al.</i> , (2001), "CCTG 575: A Randomized, Prospective Study of Phenotype Testing Versus Standard of Care For Patients Failing Antiretroviral Therapy," <i>Antiviral Therapy</i> , 6(Supplement 1): 63.

B26	Herrmann, <i>et al.</i> , (1997), "A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity," <i>Ann. NY Acad Sciences</i> , 284: 632-637.
B27	Hirsch, <i>et al.</i> , (2000), "Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection" <i>JAMA</i> , 283(18): 2417-26.
B28	Katzenstein <i>et al.</i> , (2002), "Baseline Phenotypic Susceptibility and Virologic failure over 144 weeks Among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364," Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection," 2002 9 th Conference on Retroviruses and Opportunistic Infections, Session 77 Poster Session 591-T.
B29	Katzenstein <i>et al.</i> , (2002), "The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy," 2002 9 th Conference on Retroviruses and Opportunistic Infections, Session 28 Poster Session 129.
B30	Kempf <i>et al.</i> , (2001), "Identification of Genotypic Changes in Human Immunodeficiency Virus Protease that Correlate With Reduced Susceptibility to the Protease Inhibitor Lopinavir Among Viral Isolates From Protease Inhibitor-Experienced Patients," <i>Journal of Virology</i> , 75(16): 7462-69.
B31	Maguire <i>et al.</i> , (2002), "Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 46(3): 731-738.
B32	Petropoulos, <i>et al.</i> , (2000), "A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1," <i>Antimicrobial Agents and Chemotherapy</i> , 44(4): 920-928.
B33	Race, <i>et al.</i> , (1999), "Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Therapies," <i>AIDS</i> , 13(15): 2061-2068.
B34	Rusconi, Stefano. <i>et al.</i> (2000): "Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived From Patients with Multidrug Resistance to Other Protease Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 44(5): 1328-32.
B35	Schuurman, <i>et al.</i> , (1999), "Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>Journal of Clinical Microbiology</i> , 37(7): 2291-2296.
B36	Shi, <i>et al.</i> , (1997), "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 41(12): 2781-85.
B37	Tisdale, M. <i>et al.</i> (1995): "Cross-Resistance Analysis of Human Immunodeficiency Virus Type 1 Variants Individually Selected for Resistance to Five Different Protease Inhibitors," <i>Antimicro. Agents and Chemo.</i> 39(8):1704-10.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO.

011068-035-999

APPLICATION NO

09/591,899

APPLICANT

Parkin *et al.*

FILING DATE

June 12, 2000

GROUP

1648

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SF	B01	6,033,902	3/7/00	Haseltine <i>et al.</i>	435	320.1	
SF	B02	6,242,187 B1	06/05/01	Capon <i>et al.</i>	435	6	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SF	B03	Int'l Search Report for PCT/US03/21355	5/3/04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

SF	B04	Craig <i>et al.</i> , 1998 "HIV Protease Genotype and Viral Sensitivity to HIV Protease Inhibitors Following Saquinavir Therapy", <i>AIDS</i> , 12: 1611-1618.
SF	B05	Hazuda <i>et al.</i> , 2000 "Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication In Cells," <i>Science</i> Vol. 287: 646-650.

EXAMINER

DATE CONSIDERED

5/1/4

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.